TITLE

Ingenol Mebutate for Lentigo Maligna: A Case Report

AUTHOR(S)
Gadaldi, Karolina; Feldmeyer, Laurence; Yawalkar, Nikhil; Hunger, Robert E
PUB. DATE
February 2016
SOURCE
Dermatology (10188665);Feb2016, Vol. 232 Issue 1, p24
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Background: Lentigo maligna (LM) is a melanoma in situ on sun-damaged skin, with a strong predilection to the head and neck area of the elderly. Many therapeutic modalities have been proposed in the treatment of this pathology, including surgery, cryotherapy, radiotherapy and topical imiquimod. Up to date surgical excision remains the treatment of choice with the lowest recurrence rate. Recently, a new topical treatment with ingenol mebutate has been described to be efficacious and well tolerated in the treatment of melanoma in situ.Objective: We sought to demonstrate that ingenol mebutate might be an efficacious and well-tolerated treatment in a patient suffering from LM on an aesthetically challenging location.Methods: Case report.Results: After therapeutic failure with imiquimod 5% cream, a new topical treatment with ingenol mebutate gel 0.015% once daily on 3 consecutive days was initiated. Despite visible inflammation, no macroscopic lesion clearance was observed. While the first follow-up using reflectance confocal microscopy (RCM) performed at 6 weeks after the completion of the therapy showed no signs of LM, the second follow-up examination at 12 weeks using RCM and biopsy confirmed recurrence of the lesion.Conclusion: Ingenol mebutate cannot be considered a standard treatment modality for all types of LM. Further studies are needed to evaluate the prerequisites that can ensure therapeutic success.
ACCESSION #
117536198

 

Related Articles

  • Radiotherapy in Periocular Cutaneous Malignancies: A Retrospective Study. Lazarevic, Diana; Ramelyte, Egle; Dummer, Reinhard; Imhof, Laurence // Dermatology (10188665);May2019, Vol. 235 Issue 3, p234 

    Background: Due to the importance of function and cosmetics, periocular skin malignancies represent a therapeutic challenge.Objective: To evaluate the safety and efficacy of radiotherapy (RT) treating periocular skin tumors.Methods: Data of patients with...

  • Survival with melanoma subtypes varies. APPOLD, KAREN // Dermatology Times;Nov2015, Vol. 36 Issue 11, p76 

    The article argues that thickness of the melanoma determines the survival rates for lentigo maligna (LM).

  • Lentigo Maligna - Not Always a Face and Neck Disease of the Elderly. Duarte, Ana Filipa; Sousa-Pinto, Bernardo; Barros, Ana Margarida; Haneke, Eckart; Correia, Osvaldo; Duarte, Ana Filipa; Barros, Ana Margarida // Dermatology (10188665);Jul2018, Vol. 234 Issue 1/2, p37 

    Introduction: Lentigo maligna (LM) is a rare form of in situ melanoma, frequently seen as a large patch in elderly patients. The aim of this study was to assess clinical and dermoscopic features of LM.Material and Methods: A retrospective study of LM patients presenting...

  • Melanoma subtypes are challenging to diagnose, treat. APPOLD, KAREN // Dermatology Times;Nov2015, Vol. 36 Issue 11, p62 

    The article discusses the diagnostic and treatment challenges for lentigo maligna (LM) and acral lentiginous melanoma (ALM). Topics covered include presentation patterns, population prevalence and cancer causes. Also mentioned are therapy options including Mohs surgery, a combination imiquimod...

  • Assessment of a Diagnostic Predictive Probability Model Provided by a Multispectral Digital Skin Lesion Analysis Device for Melanoma and Other High-risk Pigmented Lesions and its Impact on Biopsy Decisions. WINKELMANN, RICHARD R.; JANE YOO; TUCKER, NATALIE; WHITE, RICHARD; RIGEL, DARRELL S. // Journal of Clinical & Aesthetic Dermatology;Dec2014, Vol. 7 Issue 2, p16 

    Objective: Risk prediction models for primary malignant melanoma thus far have relied on qualitative patient information. The authors propose a quantitative diagnostic predictive probability model using Multispectral Digital Skin Lesion Analysis for melanoma and other high-risk pigmented lesions...

  • Researchers aiming to suppress therapy resistance in brain cancer.  // Medical Device Daily;7/8/2013, Vol. 17 Issue 129, p2 

    This article reports that neurooncologist professor Michael Platten and fellow researchers from the German Cancer Research Center and the Department of Neurooncology of Heidelberg University Hospital are working to find other methods of treating gliomas more effectively. Radiotherapy in...

  • Metastatic sebaceous cell carcinoma, review of the literature and use of electrochemotherapy as possible new treatment modality. Ribero, Simone; Baduel, Eugenio Sportoletti; Brizio, Matteo; Picciotto, Franco; Dika, Emi; Fierro, Maria Teresa; Macripò, Giuseppe; Quaglino, Pietro // Radiology & Oncology;Sep2016, Vol. 50 Issue 3, p308 

    The article presents a study which examines the use of electrochemotherapy as possible new treatment modality for metastatic extraorbital sebaceous carcinoma (SC). A systematic literature review for case reports of extra-ocular, cutaneous, multifocal metastasizing SC conducted between 1960 and...

  • PAGETOID PREMALIGNANT MELANOSIS AND MELANOMA: DIFFERENTIATION FROM HUTCHINSON'S MELANOTIC FRECKLE. Mishima, Yutaka; Matsunaka, Masahiro // Journal of Investigative Dermatology;Nov75, Vol. 65 Issue 5, p434 

    Twenty-three examples of pagetoid premalignant melanosis have been analyzed by clinical, histologic, histochemical, and electron microscopic techniques. Utilizing criteria based on these findings, the pagetoid lesions can be differentiated from Hutchinson's melanotic freckle and seem to be...

  • Oncolytic Virotherapy forMultipleMyeloma: Past, Present, and Future. Thirukkumaran, Chandini M.; Morris, Don G. // Bone Marrow Research;2011, p1 

    Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable. Despite recently approved novel targeted treatments such as lenalidomide and bortezomib, most MM patients' relapse is emphasizing the need for effective and welltolerated therapies for this deadly disease. The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics